15. Inclusion body myositis Clinical trials / Disease details

Clinical trials : 42 / Drugs : 60 - (DrugBank : 16) / Drug target genes : 12 - Drug target pathways : 123

2 trials found

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04789070 (ClinicalTrials.gov)	January 1, 2022	15/2/2021	Phase III Trial of Sirolimus in IBM	A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirol ...	Inclusion Body Myositis	Drug: Sirolimus;Drug: Placebo	University of Kansas Medical Center	The Perron Institute	Not yet recruiting	45 Years	N/A	All	140	Phase 3	United States
2	NCT02481453 (ClinicalTrials.gov)	July 15, 2015	13/5/2015	Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis	Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la M ...	Inclusion Body Myositis (IBM)	Drug: Rapamycin;Drug: Placebo	Institut National de la Santé Et de la Recherche Médicale, France	NULL	Completed	45 Years	85 Years	All	44	Phase 2/Phase 3	France

First Previous1Next Last